News search
Research 9 Apr 2025 A CNIC team has developed an innovative gene therapy strategy for arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5), a rare and deadly inherited condition that particularly affects young men |
Research 19 Mar 2025 The discovery, published in Nature, opens the path to new strategies for treating skin diseases and immunological disorders, with special potential for the treatment of inflammation, diabetes, and age-related conditions |
About the CNIC 18 Mar 2025 The CNIC has been allocated €405,625 for its involvement in GRACE, a project focused on developing innovative strategies to improve the detection and management of cardiovascular diseases. |
About the CNIC 19 Dec 2024 The findings of this study have been key for the development of REACT, a new research project, that will count on the collaboration of Santander Bank, and will expand the study of the age group for the prevention of cardiovascular diseases, which will include 8,000 new participants. |
Research 12 Dec 2024 iFlpMosaics is a new technology presented in Nature Methods that allows the modification and study of gene function in mouse models, advancing research on diseases caused by somatic mutations, such as cancer and vascular malformations. |
About the CNIC 12 Dec 2024 The new project, ‘The Placenta in Maternal and Fetal Cardiovascular Health and Disease’, aims to understand how the placenta influences cardiovascular health in mothers and their children, promising improvements in the prevention and treatment of related diseases |
Research 7 Oct 2024 A team of scientists from the CNIC and the CSIC has identified a key mechanism in the development of atherosclerosis in patients with the rare genetic disease Hutchinson-Gilford progeria syndrome |
About the CNIC 15 May 2024 Globally, cardiovascular diseases due to atherosclerosis – the build-up of plaque in arteries – are the leading cause of death. A new Danish-Spanish research collaboration aims to develop methods to detect atherosclerosis at earlier ages and encourage prevention. Denmark’s Novo Nordisk Foundation has granted up to EUR 23 million to cover the first 2.5 years of the REACT initiative. The initiative is expected to run for 8 years in total |
- 1 of 4
- next ›